Tord Labuda has entered the role as CEO of Alzinova, bringing extensive experience from leading positions in the pharmaceutical industry. The company is in an exciting development phase, as the clinical phase Ib study with the Alzheimer's vaccine ALZ-101 is expected to be completed in early 2025. In preparation for phase II, Alzinova is actively exploring opportunities for licensing agreements with a larger pharma company.